Abstract. The natural product tanshinone (Tan) induces apoptosis and differentiation in hepatocellular carcinoma (HCC) cells, but its clinical use is limited by its poor water solubility and the lack of appropriate formulations. In this study, Tan was encapsulated into a microemulsion (ME) composed of phospholipid, ethyl oleate, glycerol and Pluronic F68. The anticancer effects and mechanisms of action of Tan ME were tested using in vitro and in vivo HCC models. The mRNA and protein levels of apoptosis related molecules (Bcl-2 and Bax) were analyzed in H22 murine hepatoma cells and H22 tumor-bearing mice by flow cytometry, RT-PCR and immunofluorescence staining. Compared with empty ME and drug solution groups, the mRNA levels of Bax were upregulated and the mRNA and protein levels of Bcl-2 were downregulated in the H22 cells treated with Tan ME in a dose-dependent manner. The mRNA and protein levels of Bax were upregulated and the Bcl-2 levels were downregulated in the H22 tumors of animals treated with Tan ME in a dose-dependent manner. Our results suggest that as a drug delivery system, the ME enhances the antitumor effect of Tan.
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common tumor worldwide but, due to its poor prognosis, it ranks as the third most common cause of mortality from cancer (1) . Surgical therapy, chemotherapy and radiation have been used for the treatment of HCC. However, HCC remains one of the more difficult cancers to treat. Although chemotherapy is a common therapeutic strategy following surgery, it is toxic to normal tissues and this limits its use (2) . Therefore, it is important to develop safer and more effective drugs for the treatment of HCC.
Danshen has been used to treat various diseases, including heart disease, hepatitis and cancer, in China for a long time (3) .
Tanshinone (Tan) is the major lipid-soluble pharmacological constituent of danshen (4) . The diterpenoid Tan, which includes Tan I, Tan IIA, Tan IIB, dihydrotanshinone I and cryptotanshinone, has also roused extensive attention. Tanshinones have a variety of biological activities. For example, Tan I is able to enhance learning and memory, while Tan IIA has antioxidative, anti-inflammatory, antiproliferative and antitumor properties (5, 6) . Previous studies have shown that Tan IIA possesses cytotoxic activity against multiple human cancer cells, inducing apoptosis and differentiation in certain human cancer cells, including HeLa and colo205 cells (7, 8) . However, the applications of Tan have been limited due to its poor solubility, instability and low bioavailability. The poor water solubility is likely to induce opsonization and cause rapid clearance from the blood circulation following intravenous injection. Therefore, there is a need for a better drug delivery system (DDS) for Tan.
Numerous methods have been used to improve the absorption and bioavailability of poorly water-soluble drugs. One of the more attractive types of system is a microemulsion (ME) which is composed of fine oil-in-water droplets in an aqueous medium (9) . As a DDS approach, MEs are clear, stable, isotropic mixtures of oil, water and surfactant, frequently in combination with a cosurfactant (10) . MEs offer an interesting and potentially quite powerful alternative carrier system for drug delivery due to their high solubilization capacity, transparency, thermodynamic stability, ease of preparation and high diffusion and absorption rates when compared with solvents without the surfactant system (11) .
In the present study, Tan was encapsulated into an ME to provide a Tan ME formulation. The apoptosis-and differentiation-inducing effects of Tan ME were investigated in H22 cells in vitro and in vivo. Preparation of Tan ME. According to our previous study (12) , 160 mg Tan was dissolved in 38 g ethyl oleate using ultrasound, to form the oil phase of the ME. A mixture of 5.4 g phospholipid, 6 g glycerol, 10.6 g pluronic F68 and 140 ml sterile water formed the aqueous phase of the ME. The oil and aqueous phases were heated to 65˚C. The oil phase was added to the aqueous phase with magnetic stirring (Diamond, Jin Tian, China). The obtained emulsion was sheared using a high shearing emulsifier (FLUKO, Essen, Germany) for 5 min; an amount of water was then added to compensate for that lost by evaporation. The ME was emulsified further using a high pressure homogenizer (Mizuho, Osaka, Japan) under 85 MPa for 10 min and filtered through a 0.45-µm filter membrane. The ME was transferred to a 1-ml ampoule, sealed with N 2 and flow steam sterilized for 20 min.
Materials and methods

Chemicals and reagents. Tan was purchased from
Cell culture and chemical treatment. H22 cells were routinely cultured in RPMI-1640 medium with 10% (v/v) FBS, penicillin (100 U/ml) and streptomycin (100 U/ml) at 37˚C in a humidified 5% CO 2 incubator. Exponentially growing cells were exposed to 0.2 or 0.8 µg/ml concentrations of Tan ME for 48 h. The control groups were cells grown in medium containing an equivalent amount of empty ME or Tan solution.
Measurement of Bcl-2 expression by flow cytometry (FCM).
FCM was performed as reported previously (13) . At least 5,000 events were collected for each sample and washed with phosphate-buffered saline (PBS). After centrifugation, the cell pellet was resuspended in the fixation/permeabilization solution at 4˚C for 15 min. The cells were then incubated with the mouse anti-human Bcl-2 monoclonal antibody at 4˚C for 20 min in the dark. After washing twice in PBS, the cells were incubated with the FITC-conjugated goat anti-mouse IgG at 4˚C for 20 min in the dark. After washing twice in PBS, the cells were analyzed using a FACScan flow cytometer and Cell Quest software (BD Biosciences, San Jose, CA, USA).
RT-PCR assay. Total RNA was extracted from the tumor tissues or cells using TRIzol reagent. The quality and concentration of the RNA were confirmed by spectrophotometry and electrophoresis on ethidium bromide-stained agarose gels. The RT-PCR amplification was performed using the Takara RNA PCR kit (AMV) Ver 3.0. The specific primers and the amplification conditions are shown in Table I . The initial denaturation step for all genes was set at 94˚C for 5 min. Finally, an additional extension step at 72˚C for 5 min was performed. The PCR products were analyzed by electrophoresis on a 3% agarose gel with EB staining using a Gel-Pro analyzer (UVP, Upland, CA, USA).
Animals and experimental protocol. The H22 cells were collected from the ascites of the mice 8 days after inoculation to prepared a cell suspension of concentration 5.0x10 6 /ml. The Balb/c mice received a subcutaneous injection of H22 cells (1.0x10 6 in 0.2 ml) in the right axillary region (14) . From the second day after inoculation, the Balb/c mice were randomly divided into 6 groups (10/group; half male and half female). There were 3 Tan ME treatment groups comprising 3 intravenous (i.v.) dose levels (2, 4 and 8 mg/kg); a positive control group treated with 5-Fu [25 mg/kg, intraperitonealy (i.p.)]; a negative control group which received an i.v. injection of empty ME; and a Tan control group which received a solution of Tan at an i.v. dose of 8 mg/kg. The treatments were given daily for 7 consecutive days. Prior to each treatment, the mice were weighed. At the end of the experiment, all mice were sacrificed by dislocation and the body, tumor and spleen weights were determined. The tissue samples were stored at -80˚C until analysis. The tumor inhibition rate and spleen index were calculated as follows: inhibition rate (%) = (1 -tumor weight of test group/tumor weight of Tan solution group) x100; spleen index = spleen weight (mg)/body weight (g).
Immunofluorescence staining. Double immunofluorescence staining was performed as described previously (6,15). Tumor F: TACCACAGGCATTGTGATGG 310 R: AATAGTGATGACCTGGCCGT tissues were removed immediately en bloc and post-fixed for 24 h in 4% paraformaldehyde in PBS at 4˚C before cryoprotection by bathing in 30% sucrose. They were then frozen and 6-8-µm sections were prepared using a cryostat (Leica CM1850; Mannheim, Germany). The sections were rinsed with PBS 3 times for 5 min each, covered with 1% SDS solution and then incubated for 5 min at room temperature. After rinsing with PBS 3 times for 5 min each, the sections were treated with 0.3% Triton X-100, blocked with 10% horse serum and then incubated with mouse anti-human Bcl-2 monoclonal antibody (1:75) and rabbit anti-mouse Bax polyclonal antibody (1:75) at 4˚C overnight. After a PBS wash, the slides were incubated with the FITC-conjugated goat anti-mouse IgG (1:75) and TRITC-conjugated goat anti-mouse IgG (1:75) for 1 h at room temperature. The nuclei were stained with DAPI. The images of double-immunostained sections were acquired with a fluorescence microscope (Nikon, TE2000U, Tokyo, Japan).
Statistical analysis.
The results are expressed as the means ± SD. Comparisons of each group were performed by one-way analysis of variance (ANOVA) using SPSS 13.0 software. P<0.05 was considered to indicate a statistically significant result.
Results
Tan ME induces morphological changes in H22 cells.
Under an inverted light microscope, empty ME-treated and Tan solution-treated H22 cells grew well and the cell skeletons were clear. The majority of cells treated with 0.2 or 0.8 µg/ml Tan ME for 48 h were broken and necrosed (Fig. 1) .
Tan ME downregulates Bcl-2 protein levels in vitro.
The effects of the different treatments on Bcl-2 protein levels were evaluated by FCM analysis (Fig. 2) . High levels of the Bcl-2 protein were detected by FCM 48 h after empty ME treatment and the Tan solution-treated group had markedly decreased Bcl-2 protein levels compared with the empty ME-treated group. Tan ME decreased Bcl-2 protein levels markedly compared with those of the Tan solution-treated group, in a dose-dependent manner (P<0.01).
Tan ME downregulates Bcl-2 mRNA levels and upregulates Bax mRNA levels in vitro. Using semi-quantitative RT-PCR, we first examined the effects of Tan ME on the mRNA levels of Bcl-2 and Bax in cultured H22 cells. As shown in Fig. 3 , Bax mRNA expression levels were low in the Tan solution group, but 0.2 and 0.8 µg/ml Tan ME increased the mRNA levels of Bax. In the Tan solution group, Bcl-2 mRNA was highly detectable and 0.2 and 0.8 µg/ml Tan ME markedly decreased the levels of Bcl-2 mRNA (P<0.001).
Tan ME inhibits tumor growth in vivo. The treatment with 8 mg/kg Tan ME demonstrated significant inhibitory effects on the growth of the inoculated H22 cells in the mice; the inhibition rate was 47.66%. No significant differences in the tumor growth between the 2 and 4 mg/kg Tan ME-treated groups and the Tan solution-treated group were observed (Table II) . As a positive control, 5-Fu (25 mg/kg) significantly inhibited tumor growth but it also decreased the mean body weight and spleen index of the mice (Figs. 4 and 5) .
Tan ME treatment downregulates Bcl-2 and upregulates Bax mRNA levels in H22 tumors in vivo. As shown in Fig. 6 , Tan ME increased Bax mRNA levels in a dose-dependent manner (P<0.001). Compared with the Tan solution-treated group, the Bcl-2 mRNA levels were significantly decreased in the tumors from the mice treated with 2 mg/kg Tan ME (P<0.01) or 4 or 8 mg/kg Tan ME (P<0.001).
Tan ME treatment modulates the distributions of Bcl-2 and Bax in H22-transplanted tumors. We found little staining of Bax and strong staining of Bcl-2 in the Tan solution-treated Table II . Effects of body weight, spleen index and inhibition rate for H22 hepatic carcinoma in mice treated with Tan ME. tumor tissue by immunohistochemistry. Compared with the Tan solution group, 4 and 8 mg/kg Tan ME markedly increased Bax and decreased Bcl-2 in a dose-dependent manner (Fig. 7) .
Discussion
In our study, Tan was encapsulated into an ME. Phospholipid, ethyl oleate, glycerol and pluronic F68 are biocompatible components of the Tan ME that can be safely used for i.v. injection (16, 17) . The surfactant enhances the permeability of the ME. Our previous study found that empty ME itself had effects on tumor cells (12) . Therefore, in the present study, we used two control groups, an empty ME group and a Tan solution group. The results showed that there was no significant difference between the empty ME and Tan solution groups, but there were significant dose-dependent differences in the three Tan ME-treated groups, demonstrating that the ME enhances the antitumor effect of Tan.
As a positive control, 5-Fu had a significant inhibitory effect on the growth of the inoculated H22 cells in mice (the inhibition rate was 65.79%) but it significantly decreased the body weight and spleen index of the mice. Compared with the empty ME and Tan solution groups, Tan ME had no significant effects on spleen index and body weight, indicating that Tan ME caused no major side effects in the mice.
It is now well established that apoptosis is a complex biological process involving many pathways. The activation of apoptosis pathways is a key mechanism by which cytotoxic drugs kill tumor cells (18) . The induction of apoptosis is now considered to be an important method for the assessment of the clinical effectiveness of antitumor drugs (19) . Certain evidence suggests that one of the most important regulators of the apoptotic pathway is the Bcl-2 family of genes, including Bcl-2 and Bax genes (20) . One mechanism in the cell death program is the upregulation of the proapoptotic Bax protein.
An increase in Bax expression levels effects a change in the permeability of mitochondrial membranes. This leads to the release of cytochrome c and the activation of caspases, which finally proteolyze cellular components. Bcl-2 is one of the key genes known to downregulate Bax and p53 and therefore has the potency to inhibit this apoptotic pathway (21) . Su and Lin found that Tan ⅡA inhibited the proliferation of MDA-MB-231 cells in a dose-and time-dependent manner. One of the mechanisms may be through the upregulation of the expression of Bax and the downregulation of Bcl-2 expression and the induction of apoptosis (22) .
In conclusion, we demonstrate that, as a drug delivery system, the ME enhances the antitumor effect of Tan. Tan ME had significant anticancer effects in vitro and in vivo, providing a basis for the further development of this novel formulation for a new class of anticancer drugs.
